WO2012040444A3 - Treatment of patients with incipient alzheimer's disease - Google Patents
Treatment of patients with incipient alzheimer's disease Download PDFInfo
- Publication number
- WO2012040444A3 WO2012040444A3 PCT/US2011/052731 US2011052731W WO2012040444A3 WO 2012040444 A3 WO2012040444 A3 WO 2012040444A3 US 2011052731 W US2011052731 W US 2011052731W WO 2012040444 A3 WO2012040444 A3 WO 2012040444A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patients
- disease
- treatment
- incipient alzheimer
- incipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Abstract
Disclosed are methods for the treatment of patients with incipient Alzheimer's disease and the use of compounds that may be inhibitors of the enzymes that form β -amyloid (A β), e.g., A β 42, in particular γ-secretase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38601410P | 2010-09-24 | 2010-09-24 | |
US61/386,014 | 2010-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012040444A2 WO2012040444A2 (en) | 2012-03-29 |
WO2012040444A3 true WO2012040444A3 (en) | 2012-06-28 |
Family
ID=45874374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/052731 WO2012040444A2 (en) | 2010-09-24 | 2011-09-22 | Treatment of patients with incipient alzheimer's disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012040444A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
TW201444798A (en) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002047671A2 (en) * | 2000-11-17 | 2002-06-20 | Eli Lilly And Company | Lactam compound to inhibit beta-amyloid peptide release or synthesis |
US20020111343A1 (en) * | 1996-12-23 | 2002-08-15 | Jing Wu | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds |
WO2003053912A1 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS |
WO2005023772A1 (en) * | 2003-09-09 | 2005-03-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
WO2009008980A2 (en) * | 2007-07-05 | 2009-01-15 | Schering Corporation | Tetrahydropyranochromene gamma secretase inhibitors |
WO2009058552A1 (en) * | 2007-10-31 | 2009-05-07 | Bristol-Myers Squibb Company | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
-
2011
- 2011-09-22 WO PCT/US2011/052731 patent/WO2012040444A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020111343A1 (en) * | 1996-12-23 | 2002-08-15 | Jing Wu | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds |
WO2002047671A2 (en) * | 2000-11-17 | 2002-06-20 | Eli Lilly And Company | Lactam compound to inhibit beta-amyloid peptide release or synthesis |
WO2003053912A1 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS |
WO2005023772A1 (en) * | 2003-09-09 | 2005-03-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
WO2009008980A2 (en) * | 2007-07-05 | 2009-01-15 | Schering Corporation | Tetrahydropyranochromene gamma secretase inhibitors |
WO2009058552A1 (en) * | 2007-10-31 | 2009-05-07 | Bristol-Myers Squibb Company | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
Non-Patent Citations (5)
Title |
---|
BLENNOW ET AL.: "CSF markers for incipient Alzheimer's disease.", LANCET NEUROL, vol. 2, 2003, pages 605 - 613, XP004811238, DOI: doi:10.1016/S1474-4422(03)00530-1 * |
HAMPEL ET AL.: "Biological markers for early detection and pharmacological treatment of Alzheimer's disease.", DIALOGUES CLIN NEUROSCI., vol. 11, 2009, pages 141 - 157 * |
LILLY.: "Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials.", PR NEWSWIRE, 17 August 2010 (2010-08-17), pages 1 - 2 * |
MANGIALASCHE ET AL.: "Alzheimer's disease: clinical trials and drug development.", LANCET NEUROL, vol. 9, July 2010 (2010-07-01), pages 702 - 716, XP027598946, DOI: doi:10.1016/S1474-4422(10)70119-8 * |
SHAW ET AL.: "Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects.", ANN NEUROL, vol. 65, 2009, pages 403 - 413 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012040444A2 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550756A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
WO2012062925A3 (en) | Compounds and methods for treating pain | |
WO2012088290A3 (en) | Tri-variable domain binding proteins and uses thereof | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
WO2012048099A3 (en) | Nanoparticle-loaded cells | |
MY172372A (en) | Compositions and methods for lowering triglycerides | |
IL216967B (en) | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases | |
IL223819A0 (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
WO2013057570A3 (en) | Acrylic polymer formulations | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
LT2739615T (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
WO2012012278A3 (en) | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex | |
WO2012106427A3 (en) | Methods for treating diabetic foot ulcers | |
WO2011075606A3 (en) | Hyperglycosylated polypeptide variants and methods of use | |
WO2010085799A9 (en) | Compositions and method for the treatment of parkinson's disease | |
WO2013003899A8 (en) | Methods of treating or preventing rheumatic disease | |
EP2488507A4 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
WO2008050133A3 (en) | Inhibition of beta-amyloid aggregation | |
WO2012153253A3 (en) | Aromatic compounds and metal complexes thereof | |
WO2012040444A3 (en) | Treatment of patients with incipient alzheimer's disease | |
WO2010129788A3 (en) | Uses of cationic hydroxythylcellulose in oral ingestion forms, and prevention and treatment of metabolic disorders | |
WO2009091932A3 (en) | Treatment of mild dementia of the alzheimer's disease type |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11827523 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11827523 Country of ref document: EP Kind code of ref document: A2 |